Clinical deterioration after sildenafil cessation in patients with pulmonary hypertension

Vascular Health and Risk Management

Volumn 4, Issue 5, 2008, Pages 1111-1113

  Keogh, Anne M ^a   Jabbour, Andrew ^a   Hayward, Christopher S ^a   Macdonald, Peter S ^a  

^a ST VINCENT S HOSPITAL   (Australia)

Author keywords

Phosphodiesterase inhibitor; Pulmonary hypertension; Sildenafil

Indexed keywords

BOSENTAN; SILDENAFIL; VASODILATOR AGENT;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; DISEASE COURSE; DYSPNEA; ENDARTERECTOMY; FATIGUE; FEMALE; GENERAL CONDITION DETERIORATION; HEART RIGHT VENTRICLE FAILURE; HOSPITALIZATION; HUMAN; MALE; MONOTHERAPY; PULMONARY HYPERTENSION; TREATMENT WITHDRAWAL; WALKING SPEED;

ADULT; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; EXERCISE TOLERANCE; FATIGUE; FEMALE; HEART FAILURE; HUMANS; HYPERTENSION, PULMONARY; MALE; MIDDLE AGED; PHOSPHODIESTERASE INHIBITORS; PIPERAZINES; PURINES; RESPIRATION; SULFONES; TREATMENT OUTCOME; VASODILATOR AGENTS; WITHHOLDING TREATMENT;

EID: 56849100939     PISSN: 11766344     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Atz AM, Wessel DL. 1999. Sildenafil ameliorates effects of inhaled nitric oxide withdrawal. Anesthesiology, 91:307-10.
2. Channick RN, Simonneau G, Sitbon O, et al. 2001. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet, 358:1119-23.
3. Corbin JD, Francis SH. 1999. Cyclic GMP phosphodiesterase-5: target of sildenafil. J Biol Chem, 274:13729-32.
4. Galie N, Ghofrani HA, Torbicki A, et al. 2005. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med, 353:2148-57.
5. Ghofrani HA, Wiedemann R, Rose F, et al. 2002. Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension. Ann Intern Med, 136:515-22.
6. Jabbour A, Keogh A, Hayward C, et al. 2007. Chronic sildenafil lowers transpulmonary gradient and improves cardiac output allowing successful heart transplantation. Eur J Heart Fail, 9:674-7.
7. Klepetko W, Mayer E, Sandoval J, et al. 2004. Interventional and surgical modalities of treatment for pulmonary arterial hypertension. J Am Coll Cardiol, 43:73S-80.
8. Kulkarni A, Singh TP, Sarnaik A, et al. 2004. Sildenafil for pulmonary hypertension after heart transplantation. J Heart Lung Transplant, 23:1441-4.
9. Lepore JJ, Maroo A, Pereira NL, et al. 2002. Effect of sildenafil on the acute pulmonary vasodilator response to inhaled nitric oxide in adults with primary pulmonary hypertension. Am J Cardiol, 90:677-80.
10. Michelakis E, Tymchak W, Lien D, et al. 2002. Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: comparison with inhaled nitric oxide. Circulation, 105:2398-403.
11. Rabe KF, Tenor H, Dent G, et al. 1994. Identification of PDE isozymes in human pulmonary artery and effect of selective PDE inhibitors. Am J Physiol, 266:L536-43.
12. Rich S, McLaughlin VV. 1999. The effects of chronic prostacyclin therapy on cardiac output and symptoms in primary pulmonary hypertension. J Am Coll Cardiol, 34:1184-7.
13. Sheth A, Park JE, Ong YE, et al. 2005. Early haemodynamic benefit of sildenafil in patients with coexisting chronic thromboembolic pulmonary hypertension and left ventricular dysfunction. Vascul Pharmacol, 42:41-5.
14. Wilkens H, Guth A, Konig J, et al. 2001. Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension. Circulation, 104:1218-22.
15. Zhao L, Mason NA, Morrell NW, et al. 2001. Sildenafil inhibits hypoxia-induced pulmonary hypertension. Circulation, 104:424-8.